Pediatrix Medical Group Inc (MD) concluded trading on Thursday at a closing price of $13.78, with 0.44 million shares of worth about $6.1 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 4.31% during that period and on July 03, 2025 the price remained unchanged. Currently the company’s common shares owned by public are about 85.81M shares, out of which, 84.40M shares are available for trading.
Stock saw a price change of 1.10% in past 5 days and over the past one month there was a price change of -0.14%. Year-to-date (YTD), MD shares are showing a performance of 93.81% which increased to 5.03% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.62 but also hit the highest price of $17.67 during that period. The average intraday trading volume for Pediatrix Medical Group Inc shares is 875.79K. The stock is currently trading -0.47% below its 20-day simple moving average (SMA20), while that difference is down -0.27% for SMA50 and it goes to 0.32% higher than SMA200.
Pediatrix Medical Group Inc (NYSE: MD) currently have 85.81M outstanding shares and institutions hold larger chunk of about 88.71% of that.
The stock has a current market capitalization of $1.18B and its 3Y-monthly beta is at 1.22. It has posted earnings per share of -$1.01 in the same period. It has Quick Ratio of 1.81 while making debt-to-equity ratio of 0.83. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MD, volatility over the week remained 3.30% while standing at 2.87% over the month.
Stock’s fiscal year EPS is expected to rise by 10.27% while it is estimated to increase by 3.12% in next year. EPS is likely to shrink at an annualized rate of 5.28% for next 5-years, compared to annual growth of 41.89% made by the stock over the past 5-years.
Coverage by Jefferies stated Pediatrix Medical Group Inc (MD) stock as a Buy in their note to investors on September 26, 2024, suggesting a price target of $14 for the stock. On June 07, 2024, Deutsche Bank Upgrade their recommendations, while on September 27, 2021, SVB Leerink Initiated their ratings for the stock with a price target of $29. Stock get a Hold rating from Stifel on June 23, 2021.
